Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334535 | 1.00 | REN (0.55) | RENMMP1CYP3A4 | |
| SCHEMBL220327 | 1.00 | REN (0.55) | RENMMP1CYP3A4 | |
| SCHEMBL8228765 | 0.90 | REN (0.52) | REN | |
| SCHEMBL8269150 | 0.88 | REN (0.60) | REN | |
| SCHEMBL22899046 | 0.88 | ALOX15 (0.55) | REN | |
| SCHEMBL8229073 | 0.88 | REN (0.54) | REN | |
| SCHEMBL14476482 | 0.88 | REN (0.54) | REN | |
| SCHEMBL4300113 | 0.87 | REN (0.52) | REN | |
| SCHEMBL29375920 | 0.87 | REN (0.52) | REN | |
| SCHEMBL188719 | 0.87 | REN (0.52) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012078147-A1 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PRODUCTION OF ALISKIREN | WATSON LABORATORIES, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | claimed |
| CN-109400553-B | Preparation method of aliskiren intermediate | 常州红太阳药业有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9187409-B2 | Synthesis of Aliskiren | MYLAN LABORATORIES LIMITED (IN) | 2015-11-17 | — | — | US | disclosed |
| US-9187409-B2 | Synthesis of Aliskiren | MYLAN LABORATORIES LIMITED (IN) | 2015-11-17 | — | — | US | disclosed |
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| US-6800769-B2 | CHEMICAL INTERMEDIATES | SPEEDEL PHARMA AG (CH) | 2004-10-05 | — | — | US | disclosed |
| EP-1303478-B1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED OCTANOYL AMIDES | SPEEDEL PHARMA AG (CH) | 2004-05-26 | — | — | EP | disclosed |
| US-20030181765-A1 | Process for the preparation of substituted octanoyl amides | NODEN PHARMA DAC (IE) | 2003-09-25 | — | — | US | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181765-A1 | Process for the preparation of substituted octanoyl amides | CEL, HDHD5, LPO | REN 191/4885MMP1 1993/4885CYP3A4 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.